LIPO Research | Milton Maxwell

LIPO

Lipella Pharmaceuticals Inc.

0.2960

-0.0130-4.21%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

1.37M

P/E (TTM)

Basic EPS (TTM)

-2.26

Dividend Yield

Recent Filings

10-Q

Q3 FY2025 results

11/14/25Nov 14, 2025

Lipella narrowed its Q3 operating loss to $1.3M from $1.5M y/y, while R&D expenses dropped 31% to $721K on lower stock option costs, yet G&A rose 12% to $553K from higher outside services. No revenue marked the 2022 NIH grant's full depletion after Q2. YTD net loss hit $3.9M on $216K grants, with operating cash burn at $3.8M partly offset by $3.5M in preferred stock raises; cash ended at $1.9M. EPS held at -$0.28 (anti-dilutive). Cash runway fades fast. Nasdaq delisting crimps liquidity.

8-K

Board member retires

10/21/25Oct 21, 2025

Lipella Pharmaceuticals' board member Naoki Yoshimura announced his retirement effective December 31, 2025, after notifying the company on October 20. No disagreements with management on operations, policies, or practices triggered the move. Smooth transition ahead.

8-K

10/9/25Oct 9, 2025

8-K

Positive Phase 2a LP-10 results

9/18/25Sep 18, 2025

Lipella announced positive Phase 2a results for LP-10 oral rinse in oral lichen planus on September 18, 2025. All 27 patients completed the 4-week trial with no serious adverse events and minimal systemic exposure—76% of blood tacrolimus levels undetectable. Statistically significant efficacy hit all endpoints. LP-10 advances to Phase 2b.

10-Q

Q2 FY2025 results

8/14/25Aug 14, 2025

Lipella's Q2 grant revenue fell 36% y/y to $86.7k (derived), fully depleting its NIH award, while R&D jumped 20% to $791.6k on LP-310 trial outside services and G&A rose 53% to $651.7k from legal/accounting fees, driving operating loss wider to $1.36M (42% y/y, derived). Net loss hit $1.33M or $(0.31) diluted EPS, confirmed anti-dilutive on 4.3M shares. Cash climbed to $2.78M after $3.46M preferred/warrant financing offset $2.86M operating burn; no debt beyond leases. Nasdaq delisted June 20 over shareholder approval rules.

About

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

CEO

Dr. Jonathan Kaufman M.B.A., Ph.D.

IPO

12/19/2022

Website

https://lipella.com

Employees

Sector

Healthcare

Industry

Biotechnology